Drug Profile


Alternative Names: IBPM005IX; IBPM005IX (biosimilar) - Inbiopro Solutions

Latest Information Update: 16 Aug 2013

Price : $50

At a glance

  • Originator Inbiopro Solutions
  • Class Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Ankylosing spondylitis; Crohn's disease; Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 16 Aug 2013 Clinical trials in Psoriatic arthritis in India (Parenteral) during 2013
  • 16 Aug 2013 Clinical trials in Juvenile rheumatoid arthritis in India (Parenteral) during 2013
  • 16 Aug 2013 Clinical trials in Crohn's disease in India (Parenteral) during 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top